Gene Therapy Explained: Treating Disease by Fixing Genes

Strategies for Gene Therapy

Gene therapy encompasses several distinct strategies depending on the nature of the disease being treated. Gene addition (also called gene augmentation or gene replacement) delivers a functional copy of a defective gene into cells, providing the missing protein without removing the original mutant gene. This is the most established approach and works well for recessive disorders where a single functional copy of the gene produces sufficient protein to restore normal function. The added gene is typically driven by a promoter optimized for the target tissue to ensure appropriate expression levels.

Gene editing uses programmable nucleases (most commonly CRISPR-Cas9, but also zinc finger nucleases and TALENs) to correct the disease-causing mutation directly in the patient genome. Rather than adding an extra gene copy, this approach fixes the native gene at its normal chromosomal location, preserving natural regulatory control over expression. Gene editing can correct point mutations, remove pathological repeat expansions, delete regulatory silencers to reactivate genes, or disrupt harmful genes. The precision of this approach is its major advantage, but delivery of editing machinery to sufficient cells remains challenging for most tissues.

Gene silencing uses RNA interference (small interfering RNA or short hairpin RNA), antisense oligonucleotides, or other mechanisms to reduce expression of a harmful gene. This strategy is appropriate for dominant gain-of-function disorders where the mutant protein actively causes damage, or for conditions where reducing expression of a normal gene provides therapeutic benefit. For example, silencing the transthyretin gene treats hereditary transthyretin amyloidosis by preventing production of the misfolding protein that deposits in tissues.

Cell-based gene therapy combines gene modification with cell transplantation. Patient cells (typically hematopoietic stem cells or T cells) are collected, genetically modified outside the body using viral vectors or gene editing, and returned to the patient. This approach underpins CAR-T cell therapy for cancer (where patient T cells are engineered to recognize tumor antigens) and gene therapy for blood disorders (where hematopoietic stem cells are corrected and transplanted back after myeloablative conditioning).

Delivery Vehicles: Viral Vectors

The therapeutic gene must be delivered into target cells efficiently and safely, which remains the central technical challenge of gene therapy. Viral vectors are the most common delivery vehicles because viruses have evolved sophisticated mechanisms over millions of years for entering cells, trafficking to the nucleus, and delivering genetic cargo. Engineering these viruses for therapeutic use involves removing the viral genes responsible for replication and pathogenesis, replacing them with the therapeutic gene while retaining the packaging and cell-entry machinery.

Adeno-associated viruses (AAV) are the most popular vectors for in vivo gene therapy because they do not cause human disease, rarely integrate into the host genome (reducing insertional mutagenesis risk), can infect both dividing and non-dividing cells, and maintain gene expression for years in post-mitotic tissues. Different AAV serotypes (AAV1 through AAV9 and engineered variants) have different tissue tropisms: AAV8 and AAV5 target liver efficiently, AAV9 crosses the blood-brain barrier and targets neurons and muscle, AAV2 targets retinal cells, and engineered capsids like AAV-PHP.eB show enhanced central nervous system transduction. The major limitation of AAV vectors is their small packaging capacity (approximately 4.7 kilobases), which excludes large genes like dystrophin (the gene mutated in Duchenne muscular dystrophy).

Lentiviral vectors (derived from HIV-1) integrate their cargo permanently into the host cell genome, providing stable gene expression that persists through all subsequent cell divisions. This makes them ideal for ex vivo gene therapy of blood disorders, where gene-corrected hematopoietic stem cells must maintain the therapeutic gene through thousands of cell divisions as they regenerate the entire blood system over the patient lifetime. Modern self-inactivating (SIN) lentiviral designs delete the viral enhancer elements from the integrated provirus, substantially reducing the risk of activating nearby oncogenes through insertional mutagenesis.

Non-viral delivery systems are gaining attention as alternatives to viral vectors. Lipid nanoparticles (LNPs) encapsulate mRNA or gene editing components for delivery to cells, primarily targeting the liver after intravenous administration. LNPs were validated at massive scale during the COVID-19 pandemic (mRNA vaccines use this technology) and are now being applied to gene therapy and gene editing applications. Their advantages include large cargo capacity, lack of pre-existing immunity, and established manufacturing processes, though their tissue tropism remains more limited than engineered viral vectors.

Ex Vivo vs In Vivo Approaches

Ex vivo gene therapy removes cells from the patient, modifies them in the laboratory under controlled conditions, and transplants them back. This approach allows quality control testing of the modified cells before infusion, avoids exposing the patient to viral vectors directly, and enables efficient transduction in culture conditions optimized for the cell type. The standard application is for blood disorders: the patient hematopoietic stem cells are collected (mobilized from bone marrow into blood and harvested by apheresis), genetically corrected using lentiviral vectors or CRISPR, and returned via intravenous infusion after myeloablative chemotherapy clears space in the bone marrow niche. The corrected stem cells then engraft and repopulate the entire blood system.

In vivo gene therapy delivers the therapeutic vector directly into the patient body, targeting cells in their natural tissue environment. This approach is necessary for tissues where cells cannot be easily removed and returned (such as the brain, retina, muscle, and liver). Route of administration determines which tissues are transduced: subretinal injection places AAV vectors directly adjacent to retinal photoreceptor cells, intravenous AAV infusion primarily targets the liver (which receives the majority of blood flow), intrathecal injection delivers vectors to the central nervous system through cerebrospinal fluid, and intramuscular injection targets local muscle tissue.

Approved Gene Therapies

Luxturna (voretigene neparvovec), approved in 2017, treats RPE65-associated inherited retinal dystrophy by delivering functional RPE65 genes via AAV2 directly to retinal pigment epithelium cells through subretinal injection. RPE65 produces a protein essential for the visual cycle, and its absence causes progressive vision loss leading to blindness. Clinical trials demonstrated substantial and sustained improvement in functional vision, including the ability to navigate obstacle courses in dim lighting, with benefits maintained for over four years after treatment.

Zolgensma (onasemnogene abeparvovec), approved in 2019, delivers the SMN1 gene via AAV9 to motor neurons throughout the body, treating spinal muscular atrophy type 1 in infants who would otherwise die or require permanent mechanical ventilation before age two. A single intravenous infusion provides the survival motor neuron protein that these children cannot produce, enabling motor milestone achievement including sitting, standing, and in some cases walking. With a list price of 2.1 million dollars per dose, it was the most expensive drug ever approved at the time.

Hemgenix (etranacogene dezaparvovec), approved in 2022, delivers factor IX genes to liver cells via AAV5, treating hemophilia B by enabling the liver to produce functional clotting factor IX protein and secrete it into the bloodstream. A single infusion provides sustained factor IX levels in the mild hemophilia range (above 5 percent of normal), eliminating or dramatically reducing spontaneous bleeding episodes and the need for prophylactic factor replacement infusions. At a list price of 3.5 million dollars, cost-effectiveness analyses suggest long-term savings compared to lifetime factor replacement therapy costing 20 to 30 million dollars.

Casgevy (exagamglogene autotemcel), approved in late 2023, uses CRISPR-Cas9 to edit patient hematopoietic stem cells ex vivo, disrupting the BCL11A erythroid enhancer to reactivate fetal hemoglobin production. This treats sickle cell disease and transfusion-dependent beta-thalassemia by providing an alternative hemoglobin that compensates for the defective adult hemoglobin. As the first approved CRISPR-based therapy, Casgevy demonstrates that precise gene editing can be translated into clinical treatment for serious genetic conditions, opening the door for editing approaches to numerous other diseases.

Challenges and Limitations

Immune responses to viral vectors represent the most significant safety and efficacy barrier. Many adults have pre-existing neutralizing antibodies to common AAV serotypes from natural childhood infections, which can completely inactivate therapeutic vectors before they reach target cells. Screening for pre-existing antibodies excludes 20 to 50 percent of potential patients (depending on serotype) from current trials. Even without pre-existing immunity, the immune system mounts responses against viral capsid proteins after administration, causing inflammation (potentially hepatotoxicity for liver-directed therapies) and preventing effective re-dosing with the same serotype.

Durability of therapeutic effect varies by approach and target tissue. Non-integrating vectors like AAV can be gradually lost from dividing cells (such as liver hepatocytes, which turn over slowly but continuously), potentially requiring re-dosing after years. In post-mitotic tissues (neurons, retinal cells, cardiomyocytes), AAV-delivered genes can persist essentially indefinitely because these cells do not divide. Integrating vectors (lentiviral) provide permanent correction regardless of cell division, but carry residual insertional mutagenesis risk. Gene editing approaches produce permanent corrections since they modify the genome itself, though delivery efficiency determines what fraction of target cells are corrected.

Cost and accessibility remain major barriers to equitable gene therapy access. Gene therapies carry multi-million-dollar price tags reflecting their complex individualized manufacturing (particularly for ex vivo approaches requiring patient-specific cell processing), small patient populations that prevent economies of scale, and curative single-dose nature that concentrates all costs at one time point. Novel payment models including outcomes-based contracts (payers pay only if the therapy works), installment plans spreading costs over years, and gene therapy-specific insurance mechanisms are being developed, but global access remains severely limited.

Manufacturing scalability constrains how many patients can receive treatment annually. Viral vector production in bioreactors, purification to pharmaceutical grade, quality testing, and patient-specific cell processing (for ex vivo therapies) create bottlenecks that limit production capacity. Scaling from clinical trial quantities (treating tens of patients) to commercial supply (potentially thousands of patients) requires substantial capital investment in manufacturing infrastructure and process optimization that is still ongoing for most products.